Zobrazeno 1 - 10
of 1 146
pro vyhledávání: '"2720 Hematology"'
Autor:
Bührer, Elias D, Amrein, Michael A, Förster, Stefan, Isringhausen, Stephan, Schürch, Christian M, Bhate, Salil S, Brodie, Tess, Zindel, Joel, Stroka, Deborah, Sayed, Mohamad Al, Nombela-Arrieta, César, Radpour, Ramin, Riether, Carsten, Ochsenbein, Adrian F
Publikováno v:
Bührer, Elias D; Amrein, Michael A; Forster, Stefan; Isringhausen, Stephan; Schürch, Christian M; Bhate, Salil S; Brodie, Tess; Zindel, Joel; Stroka, Deborah; Al Sayed, Mohamad; Nombela-Arrieta, César; Radpour, Ramin; Riether, Carsten; Ochsenbein, Adrian F (2022). Splenic red pulp macrophages provide a niche for CML stem cells and induce therapy resistance. Leukemia, 36(11), pp. 2634-2646. Springer Nature 10.1038/s41375-022-01682-2
Disease progression and relapse of chronic myeloid leukemia (CML) are caused by therapy resistant leukemia stem cells (LSCs), and cure relies on their eradication. The microenvironment in the bone marrow (BM) is known to contribute to LSC maintenance
Autor:
Fotini Vogiatzi, Julia Heymann, Kristina Müller, Dorothee Winterberg, Aneta Drakul, Thies Rösner, Lennart Lenk, Michelle Heib, Carina Lynn Gehlert, Gunnar Cario, Martin Schrappe, Alexander Claviez, Beat Bornhauser, Jean-Pierre Bourquin, Simon Bomken, Dieter Adam, Fabian-Simon Frielitz, Britta Maecker-Kolhoff, Martin Stanulla, Thomas Valerius, Matthias Peipp, Christian Kellner, Denis M. Schewe
Publikováno v:
Blood Advances. 6:4847-4858
Immunotherapy has evolved as a powerful tool for the treatment of B-cell malignancies, and patient outcomes have improved by combining therapeutic antibodies with conventional chemotherapy. Overexpression of antiapoptotic B-cell lymphoma 2 (Bcl-2) is
Autor:
Niyazi, Maximilian, Andratschke, Nicolaus, Bendszus, Martin, Chalmers, Anthony J, Erridge, Sara C, Galldiks, Norbert, Lagerwaard, Frank J, Navarria, Pierina, Munck Af Rosenschöld, Per, Ricardi, Umberto, van den Bent, Martin J, Weller, Michael, Belka, Claus, Minniti, Giuseppe
Publikováno v:
Radiotherapy and Oncology, 184:109663. Elsevier Ireland Ltd
Radiotherapy and oncology 184, 109663-(2023). doi:10.1016/j.radonc.2023.109663
Niyazi, M, Andratschke, N, Bendszus, M, Chalmers, A J, Erridge, S C, Galldiks, N, Lagerwaard, F J, Navarria, P, Munck Af Rosenschöld, P, Ricardi, U, van den Bent, M J, Weller, M, Belka, C & Minniti, G 2023, ' ESTRO-EANO guideline on target delineation and radiotherapy details for glioblastoma ', Radiotherapy & Oncology, vol. 184, pp. 109663 . https://doi.org/10.1016/j.radonc.2023.109663
Niyazi, M, Andratschke, N, Bendszus, M, Chalmers, A J, Erridge, S C, Galldiks, N, Lagerwaard, F J, Navarria, P, Munck af Rosenschöld, P, Ricardi, U, van den Bent, M J, Weller, M, Belka, C & Minniti, G 2023, ' ESTRO-EANO guideline on target delineation and radiotherapy details for glioblastoma ', Radiotherapy and Oncology, vol. 184, 109663 . https://doi.org/10.1016/j.radonc.2023.109663
Radiotherapy and oncology 184, 109663-(2023). doi:10.1016/j.radonc.2023.109663
Niyazi, M, Andratschke, N, Bendszus, M, Chalmers, A J, Erridge, S C, Galldiks, N, Lagerwaard, F J, Navarria, P, Munck Af Rosenschöld, P, Ricardi, U, van den Bent, M J, Weller, M, Belka, C & Minniti, G 2023, ' ESTRO-EANO guideline on target delineation and radiotherapy details for glioblastoma ', Radiotherapy & Oncology, vol. 184, pp. 109663 . https://doi.org/10.1016/j.radonc.2023.109663
Niyazi, M, Andratschke, N, Bendszus, M, Chalmers, A J, Erridge, S C, Galldiks, N, Lagerwaard, F J, Navarria, P, Munck af Rosenschöld, P, Ricardi, U, van den Bent, M J, Weller, M, Belka, C & Minniti, G 2023, ' ESTRO-EANO guideline on target delineation and radiotherapy details for glioblastoma ', Radiotherapy and Oncology, vol. 184, 109663 . https://doi.org/10.1016/j.radonc.2023.109663
BACKGROUND AND PURPOSE: Target delineation in glioblastoma is still a matter of extensive research and debate. This guideline aims to update the existing joint European consensus on delineation of the clinical target volume (CTV) in adult glioblastom
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c4fcc80081e764bb448ea75d32076416
https://pure.eur.nl/en/publications/9380c174-fc80-4804-8ee4-2a7701cc121d
https://pure.eur.nl/en/publications/9380c174-fc80-4804-8ee4-2a7701cc121d
Autor:
Kaidar-Person, Orit, Fortpied, Catherine, Hol, Sandra, Weltens, Caroline, Kirkove, Carine, Budach, Volker, Peignaux-Casasnovas, Karine, van der Leij, Femke, Vonk, Ernest, Valli, Mariacarla, Weidner, Nicola, Guckenberger, Matthias, Koiter, Eveline, Fourquet, Alain, Bartelink, Harry, Struikmans, Henk, Poortmans, Philip, EORTC Radiation Oncology and Breast Cancer Groups
Publikováno v:
Radiotherapy and oncology
Radiotherapy and Oncology, 172, 99-110. Elsevier Ireland Ltd
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, Vol. 172, no.1, p. 99-110 (2022)
Radiotherapy and Oncology, 172, 99-110. Elsevier Ireland Ltd
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, Vol. 172, no.1, p. 99-110 (2022)
BACKGROUND AND PURPOSE: The multicentre EORTC 22922/10925 trial (ClinicalTrials.gov, NCT00002851) was conducted between 1996 and 2004. The trial evaluated the effect of irradiation of the internal mammary and medial supraclavicular lymph node chains
TP53 mutations confer resistance to hypomethylating agents and BCL-2 inhibition in myeloid neoplasms
Autor:
Schimmer, Roman R, Kovtonyuk, Larisa Vladimirovna, Klemm, Nancy, Fullin, Jonas, Stolz, Sebastian M, Mueller, Jan, Caiado, Francisco, Kurppa, Kari J, Ebert, Benjamin L, Manz, Markus G, Boettcher, Steffen
Publikováno v:
Blood Advances. 6:3201-3206
Autor:
Willem J.A. Witlox, Bram L.T. Ramaekers, Benjamin Lacas, Cecile Le Pechoux, Alexander Sun, Si-Yu Wang, Chen Hu, Mary Redman, Vincent van der Noort, Ning Li, Matthias Guckenberger, Harm van Tinteren, Lizza E.L. Hendriks, Harry J.M. Groen, Manuela A. Joore, Dirk K.M. De Ruysscher
Publikováno v:
Radiotherapy and Oncology, 170, 95-101. ELSEVIER IRELAND LTD
Radiotherapy and Oncology, 170, 95-101. Elsevier Ireland Ltd
Radiotherapy and Oncology, 170, 95-101. Elsevier Ireland Ltd
INTRODUCTION: In stage III non-small cell lung cancer (NSCLC), prophylactic cranial irradiation (PCI) reduces the brain metastases incidence and prolongs the progression-free survival without improving overall survival. PCI increases the risk of toxi
Autor:
Wahlstedt, Isak, Andratschke, Nicolaus, Behrens, Claus P, Ehrbar, Stefanie, Gabryś, Hubert S, Garcia Schüler, Helena, Guckenberger, Matthias, Smith, Abraham George, Tanadini-Lang, Stephanie, Tascón-Vidarte, José D, Vogelius, Ivan R, van Timmeren, Janita E
Publikováno v:
Wahlstedt, I, Andratschke, N, Behrens, C P, Ehrbar, S, Gabryś, H S, Schüler, H G, Guckenberger, M, Smith, A G, Tanadini-Lang, S, Tascón-Vidarte, J D, Vogelius, I R & van Timmeren, J E 2022, ' Gating has a negligible impact on dose delivered in MRI-guided online adaptive radiotherapy of prostate cancer ', Radiotherapy and Oncology, vol. 170, pp. 205-212 . https://doi.org/10.1016/j.radonc.2022.03.013
Radiotherapy and Oncology, 170, pp. 205-212
Radiotherapy and Oncology, 170, 205-212
Radiotherapy and Oncology, 170, pp. 205-212
Radiotherapy and Oncology, 170, 205-212
Contains fulltext : 287324.pdf (Publisher’s version ) (Open Access) BACKGROUND AND PURPOSE: MR-guided radiotherapy (MRgRT) allows real-time beam-gating to compensate for intra-fractional target position variations. This study investigates the dosim
Autor:
Locatelli, Franco, Zugmaier, Gerhard, Mergen, Noemi, Bader, Peter, Jeha, Sima, Schlegel, Paul-Gerhardt, Bourquin, Jean-Pierre, Handgretinger, Rupert, Brethon, Benoît, Rossig, Claudia, Kormany, William N, Viswagnachar, Puneeth, Chen-Santel, Christiane
Publikováno v:
Blood Advances. 6:1004-1014
The safety and efficacy of blinatumomab, a CD3/CD19-directed bispecific molecule, were examined in an open-label, single-arm, expanded access study (RIALTO). Children (>28 days and
Publikováno v:
Hematology/Oncology Clinics of North America. 36:113-132
Isocitrate dehydrogenase (IDH) 1 and 2 mutations represent essential components for the diagnosis of diffuse astrocytic tumors and oligodendroglioma. IDH wild-type glial tumors include a wide spectrum of tumors with differences in prognosis and recom
Autor:
Nicole R. Bonetti, Simona Stivala, Sara Gobbato, Jürg H. Beer, Thomas F. Lüscher, Giovanni G. Camici
Publikováno v:
Journal of Thrombosis and Haemostasis. 20:375-386
BACKGROUND Sickle cell disease (SCD) is a genetic hemoglobinopathy associated with high morbidity and mortality. The primary cause of hospitalization in SCD is vaso-occlusive crisis (VOC), mediated by alteration of red blood cells, platelets, immune